Glaukos Expands its Partnership with Santen for Preserflo MicroShunt

 Glaukos Expands its Partnership with Santen for Preserflo MicroShunt

Shots:

  • The companies enter into a license agreement for the Preserflo MicroShunt superseding the previous collaboration between the two parties
  • Glaukos get exclusive commercialization rights for the MicroShunt in the US, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of Latin America and gain full control over all development activities for the MicroShunt in the same territories, including development and regulatory activities in the US
  • Santen will continue to manufacture & supply the MicroShunt for the Glaukos territories and lead development & commercialization activities elsewhere. In Jun’2020, Santen has submitted PMA to the US FDA

Click here to­ read full press release/ article | Ref: BUSINESS WIRE | Image: Glaukos

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post